Cargando…
Cost–Utility of First-Line Actinic Keratosis Treatments in Finland
INTRODUCTION: Cost–utility assessment of first-line actinic keratosis (AK) treatments for max 25 cm(2) AK field. METHODS: A probabilistic, 2-year decision tree model was used to assess costs, quality-adjusted life-years (QALY), incremental cost-effectiveness ratio (ICER), cost-effectiveness efficien...
Autores principales: | Soini, Erkki J., Hallinen, Taru, Sokka, Anna-Leena, Saarinen, Kari |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449383/ https://www.ncbi.nlm.nih.gov/pubmed/26006101 http://dx.doi.org/10.1007/s12325-015-0211-7 |
Ejemplares similares
-
Cost–utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting
por: Hallinen, Taru A., et al.
Publicado: (2010) -
Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland
por: Hallinen, Taru, et al.
Publicado: (2023) -
Administration costs of intravenous biologic drugs for rheumatoid arthritis
por: Soini, Erkki J, et al.
Publicado: (2013) -
Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients
por: Hallinen, Taru, et al.
Publicado: (2016) -
Cost-effectiveness of pulse-echo ultrasonometry in osteoporosis management
por: Soini, Erkki, et al.
Publicado: (2018)